Retrotope
Retrotope, Inc., a US pharmaceutical firm, develops fortified PUFA drugs to combat ageing and related diseases, leveraging global scientific collaborations.
Founded
2006Retrotope, Inc., a US pharmaceutical firm, develops fortified PUFA drugs to combat ageing and related diseases, leveraging global scientific collaborations.
Retrotope, Inc., founded in 2006 and headquartered in Los Altos, CA, is a clinical-stage pharmaceutical company dedicated to combating aging and age-related diseases. The company's core mission is to develop drugs based on polyunsaturated fatty acids (PUFA) fortified with heavy isotopes, known as reinforced lipids, which protect cells from damage caused by reactive oxygen species (ROS). Retrotope focuses on treating conditions such as Infantile Neuroaxonal Dystrophy (INAD), Friedreich’s Ataxia (FA), Amyotrophic Lateral Sclerosis (ALS), and Progressive Supranuclear Palsy (PSP).
Notable figures affiliated with Retrotope include President Anil Kumar, Chairman Rick Winningham, and Chief Scientific Officer Mikhail Shchepinov. The company has garnered attention for its innovative approach to drug development and has established significant global scientific collaborations. Retrotope's achievements include advancing its drug candidates through various stages of clinical trials, contributing to the broader understanding of ROS-related cellular damage, and offering new hope for patients with rare neurodegenerative diseases.
Companies similar to Retrotope include Retro Biosciences, Praetego, ReVision Therapeutics and Pharmatrophix.
Retrotope was founded in 2006.
Retrotope's headquarters is located in Los Altos, CA, US.
Retrotope's most recent funding round was for $50M (USD) in September 2020.
As of Sep 18, 2020, Retrotope has disclosed funding of $82.7M (USD). Undisclosed round amounts are excluded.
Retrotope has 13 employees as of Feb 5, 2024.
Pharmatrophix
pharmatrophix.com
